Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy, whichever is laterXx_NEWLINE_xXFemale patients are either postmenopausal for at least 1 year, are surgically sterile for at least 6 weeks, or must agree to take appropriate precautions to avoid pregnancy from screening through follow-up if of childbearing potentialXx_NEWLINE_xXFemale patients who are pregnant; a pregnancy test is required for female patients of childbearing potentialXx_NEWLINE_xXMale and female subjects of reproductive non childbearing potential or willing to take appropriate precautions to avoid pregnancy or fathering a child for the duration of study participationXx_NEWLINE_xXFemale patients who are pregnant; a pregnancy test is required for female patients of childbearing potentialXx_NEWLINE_xXPregnancy and breast feeding:\r\n* Female patients who are pregnant are ineligible\r\n* Lactating females are not eligible unless they have agreed not to breastfeed their infants during treatment and for a period of 1 month following completion of treatment\r\n* Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtainedXx_NEWLINE_xXFemale patients who are pregnant are not eligible; Note: a pregnancy test is required for female patients of childbearing potential prior to study entryXx_NEWLINE_xXFemale patients who are pregnant are ineligibleXx_NEWLINE_xXPregnant female patients are not eligible for this studyXx_NEWLINE_xXFemale patients who are pregnant are excluded; patients should not be pregnant or plan to become pregnant while on treatment; a pregnancy test prior to enrollment is required for female patients of childbearing potentialXx_NEWLINE_xXFemale patients who are pregnant are ineligibleXx_NEWLINE_xXFemale patients who are pregnant are not eligible; pregnancy tests must be obtained in girls who are post menarchalXx_NEWLINE_xXPregnancy and breast feeding\r\n* Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential\r\n* Lactating females who plan to breastfeed their infants\r\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participationXx_NEWLINE_xXFemale participants who are already pregnant or lactating, or plan to become pregnant within 6 months of the last dose of study drug are excluded. Female participants of childbearing potential must adhere to contraception guidelines. Female participants will be considered to be of nonchildbearing potential if they have undergone surgical hysterectomy or bilateral oophorectomy or have been amenorrheic for over 2 years with a screening serum follicle-stimulating hormone (FSH) level within the laboratory's reference range for postmenopausal females.Xx_NEWLINE_xXA female is eligible to enter and participate in this study if the following apply:Xx_NEWLINE_xXFemale of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraceptionXx_NEWLINE_xXPregnant female patients; breastfeeding female patients; fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 90 days after the last dose of chemotherapy or at least 30 days after the last dose of avelumab, whichever is longer.Xx_NEWLINE_xXFemale subjects:Xx_NEWLINE_xXFemale subjects must be either:Xx_NEWLINE_xXFemale subjects who are both lactating and breastfeedingXx_NEWLINE_xXPregnant female patients; breastfeeding female patients; male patients with partners currently pregnant.Xx_NEWLINE_xXFemale subjects must be either:Xx_NEWLINE_xXIf sexually active female, patient must be/have one of the following:Xx_NEWLINE_xXMale subjects must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks for any reason that his sexual partner may be pregnantXx_NEWLINE_xXMale pts must agree to never have unprotected sexual contact with a female who can become pregnant and must agree to either completely abstain from sexual contact with females who are pregnant or are able to become pregnant. The patient must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks for any reason that his sexual partner may be pregnant.Xx_NEWLINE_xXFor female subjects of childbearing potential:Xx_NEWLINE_xXFemale patients who are pregnant or currently breastfeeding; female patients of childbearing potential must have a negative serum pregnancy test prior to enrollmentXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not willing to employ effective birth control.Xx_NEWLINE_xXFemale subjects of childbearing potential must not be pregnant or breastfeedingXx_NEWLINE_xXFemale participants must either:Xx_NEWLINE_xXFemale patients who:Xx_NEWLINE_xXFemale subjects who are pregnant or breastfeeding or planning to become pregnant or breastfeed, or of childbearing potential unwilling to use an effective method of contraception while receiving, and for an additional 48 hours after the last dose of blinatumomab.Xx_NEWLINE_xXFemale subjects of childbearing potential must:Xx_NEWLINE_xXMale subjects with a female partner of childbearing potential must:Xx_NEWLINE_xXHave a female partner who is NOT of childbearing potential.Xx_NEWLINE_xXFemale subjects must be:Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test within 3 days prior to taking their first dose of BGB324. Male patients and female patients of reproductive potential must practice highly methods of contraception throughout the study and for ? 3 months after the last dose of BGB324.Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to initiating dosing. Male and female subjects with reproductive potential must agree to use acceptable contraceptive methods while on study therapy and for 12 week following their last dose of study medication.Xx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum pregnancy test within 7 days of the first administration of study drug. For the purpose of this study, female subjects of childbearing potential are defined as all female subjects after puberty unless they are postmenopausal for at least 1 year, or are surgically sterile (hysterectomy or bilateral oophorectomy or tubal ligation).Xx_NEWLINE_xXFemale subjects must not be pregnant or at risk to become pregnant during the study. Fertile male and female subjects must agree to use an effective barrier method of birth control to avoid pregnancy (for female subjects a double-barrier method of contraception, for male subjects a condom with spermicide) or total abstinence from the time of providing informed consent until 90 days after the last administration of study drug. Use of oral contraceptives is not allowed.Xx_NEWLINE_xXFemale patients who are pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study) or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapy.Xx_NEWLINE_xXFemale subjects who are pregnant or breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.Xx_NEWLINE_xXSTRATUM A: Female participants who are breastfeeding a childXx_NEWLINE_xXSTRATUM B: Female participants who are breastfeeding a childXx_NEWLINE_xXSTRATUM C: Female participants who are breastfeeding a childXx_NEWLINE_xXFemale subjects who are pregnant or breastfeeding or male or female subjects of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of study medications.Xx_NEWLINE_xXFor both male and female subjects, willingness to use adequate contraception.Xx_NEWLINE_xXFemale subject who is lactating/breastfeeding.Xx_NEWLINE_xXFemale patients who are pregnant (positive beta-HCG) or breastfeeding.Xx_NEWLINE_xXMale or female subjectsXx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test within 14 days prior to enrollment; male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatmentXx_NEWLINE_xXFemale participants must be either postmenopausal defined as:Xx_NEWLINE_xXPregnant female patients; breastfeeding female patients; and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study and for 90 days.Xx_NEWLINE_xXA female participant is eligible to participate if she is not pregnant , not breastfeeding, and at least one of the following conditions applies:Xx_NEWLINE_xXThe study treatment must be excluded in the following patients:\r\n* Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 4 months after the last dose of talimogene laherparepvec\r\n* Female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 4 months after the last dose of talimogene laherparepvec\r\n* Sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvecXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapyXx_NEWLINE_xXAll male and female subjects must follow all requirements defined in the pomalidomide Pregnancy Prevention Program.Xx_NEWLINE_xXPractice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of child bearing potential while participating in the study, during dose interruptions and for at least 28 days following pomalidomide discontinuation, even if he has undergone a successful vasectomy or practices complete abstinence.Xx_NEWLINE_xXFemale subject must either:Xx_NEWLINE_xXSexually active female and male subjects must be willing to use an effective method to avoid pregnancies.Xx_NEWLINE_xXFor this trial, male subjects must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following protocol discontinuation, even if he has undergone a successful vasectomyXx_NEWLINE_xXPatients of childbearing potential (male or female) must practice adequate contraceptionXx_NEWLINE_xXCHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Male patients with female partners of childbearing potential and female patients of childbearing potential must agree to use contraception for six months after receiving the preparative regimenXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXFemale subjects of childbearing potential must not be pregnant at screening; female patients must be either postmenopausal, free from menses for >= 2 years, surgically sterilized, or willing to use two adequate barrier methods of contraception to prevent pregnancy, or must agree to abstain from heterosexual activity throughout the study; female patients of childbearing potential must have a negative serum (beta human chorionic gonadotropin [?HCG]) or urine pregnancy test before receiving the first dose of cabozantinib or carfilzomib; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; women of reproductive potential will be counseled to use effective contraceptive\r\nmeasures to prevent pregnancy during treatment with either cabozantinib or carfilzomib; patients shall be advised not to take cabozantinib or carfilzomib treatment while pregnant or breastfeeding; if a patient wishes to restart breastfeeding after treatment, she will be advised to discuss the appropriate timing with her physicianXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or female patients of reproductive potential who are not employing an effective method of birth control from starting dose of study medications (cycle 1 day 1), including dosing interruptions through 90 days after receipt of the last dose of durvalumab; refrain from egg cell donation while taking durvalumab and for at least 90 days after the last dose of durvalumabXx_NEWLINE_xXMale subjects who are not employing an effective method of birth control from starting dose of study medications (cycle 1 day 1), including dosing interruptions through 6 months after receipt of study treatment; male subjects should agree to refrain from sperm donation while taking study treatment and for at least 6 months after the last dose of nab-paclitaxel and at least 90 days after the last dose of durvalumab; should a female partner of a male patient become pregnant or suspect she is pregnant while participating in the study, he should inform his treating physician and the female partner should call her physician immediatelyXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing two highly effective methods of birth controlXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time periodXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time periodXx_NEWLINE_xXFemale patients who are pregnant or lactating are not eligible (because treatment involves unforeseeable risks to the embryo or fetus)Xx_NEWLINE_xXFemale patients of childbearing age must have a negative serum HCG test within 7 days of study enrollment, unless prior hysterectomy or menopause (defined as age ? 55 years and twelve consecutive months without menstrual activity). Female patients should not become pregnant or breast-feed while on this study.Xx_NEWLINE_xXMale subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 30 days following treatment discontinuation, even if he has undergone a successful vasectomyXx_NEWLINE_xXFemale subjects who are pregnant or breast-feeding, or male or female patients of reproductive potential who are not willing to employ a highly effective method of contraception from screening to 180 days after the last dose of investigational therapyXx_NEWLINE_xXFemale subject is pregnant or breast-feeding, or planning to become pregnant or male subject is planning to father a child within the projected duration of the trial, starting with the pre-screening or screening visit, during study treatment and through 3 months after the last dose of talimogene laherparepvec or 4 months after the last dose of pembrolizumab, whichever is laterXx_NEWLINE_xXFemale participants must be either postmenopausal defined as:Xx_NEWLINE_xXMale or female study participants with sickle cell diseaseXx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXFemale subject must either:Xx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of azacitidine, durvalumab (MEDI4736) and/or tremelimumab therapy; lactating females must agree not to breast feed throughout this periodXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time periodXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXA female who is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 48 hours (Period 1) or 72 hours (Period 2), respectively, after the last dose of blinatumomab (Female subjects of childbearing potential should only be included in the study after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test).Xx_NEWLINE_xXFemale sexXx_NEWLINE_xXFemale patients who are pregnant or breast-feeding, or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXMen must agree to use a latex or synthetic condom during sexual contact with a pregnant female or a female who can become pregnant, for the duration of the study and for at least 4 weeks after the last drug administration, even if they have undergone a successful vasectomy.Xx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXMale subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following IP discontinuation, even if he has undergone a successful vasectomyXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapyXx_NEWLINE_xXMale subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or female of childbearing potential starting with the first dose of study therapy, during dose interruptions, and for up to 6 months following last dose of study therapy, even if he has undergone a successful vasectomyXx_NEWLINE_xXMale or female participantXx_NEWLINE_xXFemale patients must either:Xx_NEWLINE_xXMale subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following IP discontinuation, even if he has undergone a successful vasectomyXx_NEWLINE_xXThe subject is pregnant, as defined by a presumptive sign of pregnancy such as missed menses or a positive pregnancy test; NOTE: female subjects of childbearing potential are required to have a negative qualitative serum pregnancy test at the time of enrollment and within twenty-four (24) hours prior to the first dose of the investigational product\r\n* Female subject of childbearing potential is defined as follows:\r\n** Subject with regular menses\r\n** Subject with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding\r\n** Subject with history of tubal ligation\r\n* Female subject not of childbearing potential is defined as follows:\r\n** Subject who has undergone hysterectomy and/or bilateral oophorectomy\r\n** Subject who is post-menopausal, which is defined as amenorrhea for at least one (1) year in a female subject who is greater than forty-five (> 45) years oldXx_NEWLINE_xXFertile male and female patients must be willing to use a contraceptive method before, during, and for at least two months after the T cell infusionXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time periodXx_NEWLINE_xXFemale patients must not be pregnant or lactating; female patients of childbearing potential (including those < 1 year post-menopausal) and male patients must agree to use contraceptionXx_NEWLINE_xXFemale patients must not be pregnant or lactating; female patients of childbearing potential (including those < 1 year post-menopausal) and male patients must agree to use contraceptionXx_NEWLINE_xXMale or female subjects with AML with no available curative treatment options using currently available therapiesXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female subjects of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXFemaleXx_NEWLINE_xXFemale and male patients of reproductive potential must agree to use effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 180 days after the last dose of durvalumab monotherapy, whichever is the longer time period; should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXFemale subjects of childbearing potential and male subjects with female partners of childbearing potential must be willing to avoid pregnancy.Xx_NEWLINE_xXIf female, must not be pregnant (pregnancy testing will be performed locally in all female patients of childbearing potential), must not be nursing and must be one of the following:Xx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXFemale patients of any ethnic group; female patients must be surgically sterile, postmenopausal (no menses for at least one year), or using medically approved method of contraception (excluding rhythm, withdraw or abstinence)Xx_NEWLINE_xXFemale subjects who are pregnant or planning to become pregnant during the course of SABRXx_NEWLINE_xXGender: male and femaleXx_NEWLINE_xXMale sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject.Xx_NEWLINE_xXMust be female.Xx_NEWLINE_xXMale patients must agree to never have unprotected sexual contact with a female who can become pregnant and must agree to either completely abstain from sexual contact with females who are pregnant or are able to become pregnant, or he must use a latex condom every time he engages in sexual contact with females who are pregnant or may become pregnant while he is taking pomalidomide and for 1 week after he stops taking the drug, even if he has had a successful vasectomy; the patient must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks for any reason that his sexual partner may be pregnant; male patients cannot donate semen or sperm while taking pomalidomide and for at least 1 week days after completing the studyXx_NEWLINE_xXFemale and male patients (and when relevant their partners) must be willing to practice birth control (including abstinence) during and for two months after treatment, if of childbearing potential during sexual contact with a female of childbearing potentialXx_NEWLINE_xXMale sterilization (at least 6 months prior to Screening). For female patients on the study the vasectomized male partner should be the sole partner for that patientXx_NEWLINE_xXMale/female sterilizationXx_NEWLINE_xXFemale patients who are pregnant or lactating are not eligible to receive treatment but can be followed for natural historyXx_NEWLINE_xXFemale subject must either:Xx_NEWLINE_xXA sexually active male subject with female partner(s) who are of childbearing potential is eligible if:Xx_NEWLINE_xXMale or female subjects will be included. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: a) Not a woman of childbearing potential (WOCBP) OR b). A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.Xx_NEWLINE_xXFemale subjects agree not to be pregnant or lactating from beginning of the study screening until 4 months after receiving the last treatment; Male and female subjects and their sexual partners are willing and able to employ a highly effective method of birth control/contraception.Xx_NEWLINE_xXFemale participant without childbearing potential must meet at least one of the following:Xx_NEWLINE_xXFemale participant of childbearing potential must meet at least one of the following:Xx_NEWLINE_xXSexually active with female partner onlyXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time periodXx_NEWLINE_xXFemale patients who are post-menopausal or surgically sterile.Xx_NEWLINE_xXIf male, agrees to use a latex condom during any sexual contact with a female of child-bearing potential.Xx_NEWLINE_xXMale sterilization (at least 6 months prior to enrolling). For female patients on the study the vasectomized male partner should be the sole partner for that patient.Xx_NEWLINE_xXFemale patients who are breastfeeding.Xx_NEWLINE_xXFemaleXx_NEWLINE_xXPregnant or lactating patients, or fertile female patients with a positive pregnancy test, or fertile female patients unwilling to use adequate contraception during treatment and for 30 days after completion of treatmentXx_NEWLINE_xXFemaleXx_NEWLINE_xXPregnant female patients; breastfeeding female patients; fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 methods of contraception.Xx_NEWLINE_xXFemale subject who is pregnant (as verified by urine test at time of screening) or lactating or of childbearing potential and not using acceptable methods of contraception.Xx_NEWLINE_xXMale subjects must practice true abstinence or agree to use a condom during sexual contact with a female of childbearing potential or a pregnant female while on treatment (including during dose interruptions) with gemcitabine/cisplatin/nab-paclitaxel and for 6 months following gemcitabine/cisplatin/nab- paclitaxel discontinuation, even if he has undergone a successful vasectomy.Xx_NEWLINE_xXFemale participants eligible to participate if not pregnant, not breastfeeding, and not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees to follow contraceptive guidance during the treatment period and for ?150 days after the last dose of study treatmentXx_NEWLINE_xXBreast-feeding or pregnant women, or patients for whom there is a risk of conception and who are unable or unwilling to use appropriate contraception (for male and female patients up to 4 months after end of ibrutinib.)Xx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after receipt of the last dose of study drugsXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapyXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults who are of reproductive potential and are unwilling to refrain from conceiving a child during study treatmentXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or female patients of reproductive potential who are not employing an effective method of birth control from starting dose of durvalumab (cycle 1 day 1), including dosing interruptions through 90 days after receipt of the last dose of durvalumab; refrain from egg cell donation while taking durvalumab and for at least 90 days after the last dose of durvalumabXx_NEWLINE_xXFemale subjects of childbearing potential and male subjects with female partners of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 30 days following last dose. Female subjects of childbearing potential must not be breastfeeding, or planning to breastfeed, and must have a negative pregnancy test ?7 days before first study drug administration. Male subjects must also refrain from donating sperm during their participation in the study.Xx_NEWLINE_xXFemale subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 7 months after the last dose of treatment; female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 7 months after the last dose of treatment; sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvecXx_NEWLINE_xXFemale patient who is breastfeeding.Xx_NEWLINE_xXFemale patients who are pregnant are ineligibleXx_NEWLINE_xXNote: Female subjects of childbearing potential are required to have a negative qualitative serum pregnancy test at the time of enrollment and within twenty-four (24) hours prior to the first dose of the investigational product\r\n* Female subject of childbearing potential is defined as follows:\r\n** Subject with regular menses\r\n** Subject with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding\r\n** Subject with history of tubal ligation\r\n* Female subject not of childbearing potential is defined as follows:\r\n** Subject who has undergone hysterectomy and/or bilateral oophorectomy\r\n** Subject who is post-menopausal, which is defined as amenorrhea for at least one (1) year in a female subject who is greater than forty-five (> 45) years oldXx_NEWLINE_xXFemale patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing effective methods of birth control for at least 6 months after completion of the last dose of MEDI4736 and AC chemotherapyXx_NEWLINE_xXFemale patients who are pregnant are ineligibleXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female subjects of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXFemale and male patients (and when relevant their partners) must be willing to practice birth control (including abstinence) during and for two months after treatment if female of childbearing potential or male having sexual contact with a female of childbearing potentialXx_NEWLINE_xXFemale patients who are pregnant are ineligibleXx_NEWLINE_xXDONOR: Lactating femaleXx_NEWLINE_xXWomen of childbearing potential only: negative serum pregnancy test done =< 7 days prior to registration; NOTE: female subjects who are pregnant or nursing are excluded from this study; there is no specific mitigation strategy for vismodegib toxicity; however, male patients should be made aware of it during the consent process; although this effect is expected to be reversible with discontinuation of dosing, long-term effects on male fertility cannot be excluded at this timeXx_NEWLINE_xXFemale participants must not be breastfeedingXx_NEWLINE_xXFemale patients who are post-menarchal must have a negative pregnancy test; lactating female patients must agree not to breast-feed while on this trial; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive methodXx_NEWLINE_xXFemale patients who are pre-menopausal or have experienced menopause for less than 2 years must have a negative serum pregnancy test < 72 hours before starting study treatment. Male and female patients with reproductive potential must agree to use appropriate contraceptive methods while on study and for 3 months after the last dose of CPI-0610. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediatelyXx_NEWLINE_xXMale patients with female partners of childbearing potential and female patients of childbearing potential must agree to use contraception for four months after receiving the preparative regimen or while on vemurafenibXx_NEWLINE_xXFemale subjects who are pregnant intend to become pregnant or are nursing; female subjects with child-bearing potential must have a negative pregnancy test within one week of enrollmentXx_NEWLINE_xXFemale patients who are pregnant are not eligible for this studyXx_NEWLINE_xXFemale patients who are breastfeeding are not eligible for this study unless they agree not to breastfeedXx_NEWLINE_xXFemale subject must either:Xx_NEWLINE_xXFemale Children of Childbearing Potential (FCCBP), Female of Childbearing Potential (FCBP) and male subjects that have reached puberty must agree to undergo physician-approved reproductive education and discuss the side effects of the study therapy on reproduction with parent(s) and/or guardian(s).Xx_NEWLINE_xXAll male and female subjects must follow all requirements defined in the Pregnancy Prevention Program.Xx_NEWLINE_xXMale and female subjectsXx_NEWLINE_xXMale sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patientXx_NEWLINE_xXFemale subjects of childbearing potential must not be pregnant at screening.Xx_NEWLINE_xXIf female, patient is postmenopausalXx_NEWLINE_xXMale subjects agree in writing to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 7 months following IP discontinuation, even if he has undergone a successful vasectomy.Xx_NEWLINE_xXMale and female subjectsXx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXWomen of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)Xx_NEWLINE_xXMale subjects with a female partner of childbearing potential must:Xx_NEWLINE_xXFemale partners of male subjects who are of childbearing potential must also adhere to one of the following:Xx_NEWLINE_xXWomen of childbearing potential or female partners of male subjects must abide by the contraception measures defined by the protocolXx_NEWLINE_xX3. Female subjects of childbearing potential1 may participate, providing they meet the following conditions:Xx_NEWLINE_xXAgree to abstain from breastfeeding during study participation and for at least 90 days after the last dose of IP. c. Agree to abstain from breastfeeding during study participation and for at least 90 days after the last dose of IP. d. Refrain from egg cell donation while taking durvalumab and for at least 90 days after the last dose of durvalumab. A female subject of childbearing potential (FCBP) is a female who:Xx_NEWLINE_xXFemale subject must either:Xx_NEWLINE_xXMale or non-pregnant, non-lactating femaleXx_NEWLINE_xXMale participants who disagree to practice true abstinence or disagree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and at least 3 months following study treatment discontinuation, even if he has undergone a successful vasectomy.Xx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXSubjects unwilling to use acceptable methods of contraception. -Female subjects should refrain from breastfeeding throughout this period.Xx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control from screening to 90 days after the last dose of tremelimumab monotherapyXx_NEWLINE_xXPregnant femaleXx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXFemale who has been post-menopausal for more than one (1) year or female of childbearing potential agreeing to use a highly efficient method of contraception (i.e. a method with less than 1% failure rate [e.g. sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomized partner or combined birth control pills]) Female of childbearing potential must have a negative from Screening until 90 days after last dose of INTUVAX and/or until completed sunitinib treatment whichever occurs later.blood pregnancy test at Screening, and if randomized to vaccination a negative blood or urine pregnancy test within one (1) day before each dose of Intuvax) and must not be lactating.Xx_NEWLINE_xXMale or non-pregnant and non-lactating femaleXx_NEWLINE_xXMale or FemaleXx_NEWLINE_xXFemale patients who are pregnant are ineligibleXx_NEWLINE_xXA female subjects is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:Xx_NEWLINE_xXFemale subject must either:Xx_NEWLINE_xXEffective contraception for both male and female subjects if the risk of conception existsXx_NEWLINE_xXFemale subjects who are pregnant or breast-feeding are not eligible; should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; likewise, should a female partner of a male patient become pregnant or suspect she is pregnant while participating in the study, he should inform his treating physician and the female partner should call her physician immediatelyXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or female patients of reproductive potential who are not employing an effective method of birth control from starting dose of durvalumab (cycle 1 day 1), including dosing interruptions through 90 days after receipt of the last dose of durvalumab are not eligible; female subjects should agree to refrain from egg cell donation while taking durvalumab and for at least 90 days after the last dose of durvalumabXx_NEWLINE_xXMale subjects who are not employing an effective method of birth control from starting dose of durvalumab (cycle 1 day 1), including dosing interruptions through 90 days after receipt of the last dose of durvalumab are not eligible; male subjects should agree to refrain from sperm donation while taking durvalumab and for at least 90 days after the last dose of durvalumab; should a female partner of a male patient become pregnant or suspect she is pregnant while participating in the study, he should inform his treating physician and the female partner should call her physician immediatelyXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXFemale subject is either:Xx_NEWLINE_xXOne of the following is required: Placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female subject or female partner of a male subject; Additional barrier method: contraceptive sponge or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female subject or female partner of a male subject. For male subject or male partner of female subject, vasectomy or other procedure resulting in infertility (e.g., bilateral orchiectomy) performed at least 6 months before Screening. Tubal ligation in the female partner of a male subject performed at least 6 months before Screening. Established and ongoing use of oral, injected, or implanted hormonal contraceptive by female partner of a male subject.Xx_NEWLINE_xXFemale subject must not be breastfeeding at Screening or during the study period and for 3 months after final study drug administration.Xx_NEWLINE_xXFemale patients who are pregnant or breastfeeding. Female patients of childbearing potential must have a negative pregnancy test and agree to use adequate contraception for the duration of the trial.Xx_NEWLINE_xXSubjects unwilling to use acceptable methods of contraception. -Female subjects should refrain from breastfeeding throughout this period.Xx_NEWLINE_xXFemale participants of childbearing potential must not be pregnant at screeningXx_NEWLINE_xXIf female, subject must be either:Xx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXFemale patients of childbearing age must have a negative serum HCG test unless prior hysterectomy or menopause (defined as age ? 55 and twelve consecutive months without menstrual activity). Female patients should not become pregnant or breast-feed while on this study. Sexually active male and female patients should use effective birth controlXx_NEWLINE_xXMale or non-pregnant femaleXx_NEWLINE_xXFemale subject must be either:Xx_NEWLINE_xXSex: male or female.Xx_NEWLINE_xXPregnant, lactating or actively breastfeeding female subjectsXx_NEWLINE_xXFemale participants eligible to participate if not pregnant, not breastfeeding, and is not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees to follow contraceptive guidance during the treatment period and for ?180 days after the last dose of study treatmentXx_NEWLINE_xXMale and female patients able to have children must agree to use 2 effective methods of contraception throughout the study and for up to 45 days for female patients and 105 days for male patients after the last dose.Xx_NEWLINE_xXFemale subjects who are lactating, pregnant or both male and female subjects with reproductive potential who refuse to practice medically accepted methods for contraception over the period from study consent to 90 days following the last dose of study treatmentXx_NEWLINE_xXMale subjects must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks for any reason that his sexual partner may be pregnantXx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXFemale patients who are pregnant are not eligibleXx_NEWLINE_xXLactating female or female who becomes pregnant prior to transition to this study.Xx_NEWLINE_xXA female is eligible to enter and participate in this study if she is of non-childbearing potential (i.e., physiologically incapable of becoming pregnant) or if she is of childbearing potentialXx_NEWLINE_xXMale or non-pregnant, non-lactating female patientsXx_NEWLINE_xXNursing female.Xx_NEWLINE_xXFemale subjects of childbearing potential must have a negative pregnancy test and both male and female (of childbearing potential) subjects must agree to use reliable methods of contraception during the study.Xx_NEWLINE_xXPatients (male and female) having procreative potential who are not using adequate contraception or practicing abstinenceXx_NEWLINE_xXPregnant and nursing women, or women planning to become pregnant within 6 months after the end of treatment, are excluded from this study; a negative pregnancy test will be required of women of child-bearing age within 72 hours of study enrollment; subjects (male or female) who are not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment are excludedXx_NEWLINE_xXEXPANSION COHORT ONLY: Female subjects who are pregnant or lactating are not eligible to participate in this studyXx_NEWLINE_xXMale or female subjects of the age defined in the original protocol they were enrolled.Xx_NEWLINE_xXFemale subjects of childbearing potential must not be pregnant at screening.Xx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab (MEDI4736) + tremelimumab combination therapy or 90 days after the last dose of durvalumab (MEDI4736) monotherapy, whichever is the longer time periodXx_NEWLINE_xXEffective contraception for both male and female subjects if risk of conception exists.Xx_NEWLINE_xXA female subject is eligible to enter the study if she is:Xx_NEWLINE_xXFemale patients must not be pregnant or lactating; female patients of childbearing potential (including those < 1 year postmenopausal) and male patients must agree to use contraceptionXx_NEWLINE_xXPatients must meet the following conditions related to reproductive health:\r\n* Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment\r\n* Female patients with infants must agree not to breastfeed their infants while on this study\r\n* Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 6 months after study treatmentXx_NEWLINE_xXPregnant female patients; breastfeeding female patients; males patients with partners currently pregnant, male patients able to father children and female patients of childbearing potential who are unwilling or unable to use two (2) highly effective methods of contraception as outlined in this protocol for the duration of the study and for 28 days after last dose of PF-04136309, and for 6 months after last dose of nab-paclitaxel, gemcitabine, or both.Xx_NEWLINE_xXFemale subject must either:Xx_NEWLINE_xXPregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within 7 days prior to start of treatment); male or female of reproductive potential has agreed to use effective contraception method for duration of study treatmentXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time periodXx_NEWLINE_xXFemale subject must either:Xx_NEWLINE_xXA sexually active male subject with female partner(s) who are of childbearing potential is eligible if:Xx_NEWLINE_xXTubal litigation in the female partnerXx_NEWLINE_xXFemale subject must either:Xx_NEWLINE_xXTubal ligation in the female partner.Xx_NEWLINE_xXFemale subjects who are of non-reproductive potential (Female subjects of reproductive potential must have a negative serum pregnancy test upon study entry).Xx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXMale patients must use condoms at all times, even after a vasectomy, during sexual intercourse with female partners of reproductive potential during treatment with vismodegib and for 2 months after the last doseXx_NEWLINE_xXMale or female, and:Xx_NEWLINE_xXMale or female patients and no race-ethnic restrictionsXx_NEWLINE_xXFemale subjects of childbearing age must have a negative urine HCG test unless prior hysterectomy or menopause (defined as age above 55 and twelve months without menstrual activity). Female subjects should not become pregnant or breast-feed while on this study. Sexually active male and female subjects should use effective birth control.Xx_NEWLINE_xXNegative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drugXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Female patient is breastfeedingXx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Female patient is breastfeedingXx_NEWLINE_xXMale subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following treatment discontinuation, even if he has undergone a successful vasectomyXx_NEWLINE_xXMale or femaleXx_NEWLINE_xXRefuse of use of contraception during trial (both male and female patients)Xx_NEWLINE_xXPatient is a female who is pregnant, lactating, or is planning a pregnancy during study participation, or in the follow-up period.Xx_NEWLINE_xXFemale patients may not be breastfeeding at screening and must not breastfeed during study participation through 45 days after the last dose of study drug.Xx_NEWLINE_xXMale patients must use condoms at all times, even after a vasectomy, during sexual intercourse with female partners of reproductive potential during treatment with vismodegib and for 3 months after the last doseXx_NEWLINE_xXSubjects who desire to get pregnant a female of childbearing potential within the next 1.5 yearsXx_NEWLINE_xXFemale patients who are pregnant are ineligibleXx_NEWLINE_xXFemale participantsXx_NEWLINE_xXMale and female subjectsXx_NEWLINE_xX(Female only) not breastfeedingXx_NEWLINE_xX(Female only) is not breastfeedingXx_NEWLINE_xXDONOR: (Female only) is not breastfeedingXx_NEWLINE_xXFemale patients who are pregnant or breast-feeding. All post menarche female patients must have a pregnancy test at screening.Xx_NEWLINE_xXMale or Female (non-pregnant)Xx_NEWLINE_xXMale partner sterilization, occurring at least 6 months prior to screening. For female subjects on the study, the vasectomized male partner should be their sole partner.Xx_NEWLINE_xXFemale subject must either:Xx_NEWLINE_xXFemale subject must be either:Xx_NEWLINE_xXpractice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 6 months following study drug discontinuation, even if he has undergone a successful vasectomy.Xx_NEWLINE_xXFemale patients and male patients with female partners of child bearing potential must be using adequate contraception.Xx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXFemale patients of childbearing potential (see Section 4.2.2.3) and male who are able to father a childXx_NEWLINE_xXFemale patient is pregnant, breastfeeding, or premenopausal and not using an effective method of contraceptionXx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXPregnancy and breast feeding\r\n* Female patients who are pregnant are ineligible\r\n* Lactating females are not eligible unless they have agreed not to breastfeed their infants\r\n* Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained\r\n* Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participationXx_NEWLINE_xXPregnant or lactating in female patients, if applicable (childbearing potential who have received a reduced intensity conditioning regimen)Xx_NEWLINE_xXMust be female and postmenopausal.Xx_NEWLINE_xXPregnant or lactating female or female of child-bearing potential not employing adequate contraception.Xx_NEWLINE_xXFemale patients who are pregnant or lactating or planning to become pregnant within 6 months after the end of the treatment (female patients of child-bearing potential must have negative pregnancy test =< 72 hours before registration)Xx_NEWLINE_xXFemale of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraceptionXx_NEWLINE_xXFemale participants must not be pregnant or breast-feeding. Female participants of childbearing potential and fertile male participants must agree to use a highly effective contraceptive during the trial and for a period of at least 6 months following the last administration of trial drug(s)Xx_NEWLINE_xXMale or female aged 16 years; a female is eligible to enter and participate in the study if she is:Xx_NEWLINE_xXof non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post- menopausal); or,Xx_NEWLINE_xXAny female that is trying to get pregnantXx_NEWLINE_xXPregnant or lactating female; female subjects who are lactating are eligible if they discontinue nursing prior to the first dose of study drug and refrain from nursing throughout the treatment period and for 14 days following the last dose of study drugXx_NEWLINE_xXA female subject is eligible to participate if she is of:Xx_NEWLINE_xXMale or female for phase I and female for phase II and any raceXx_NEWLINE_xXMust practice complete abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 28 days following study drug discontinuation, even if he has undergone a successful vasectomy.Xx_NEWLINE_xXFertile males with female partners who are not willing to use contraception or whose female partners are not using adequate contraceptive protectionXx_NEWLINE_xXFemale patients who are pregnant or breast-feeding are not eligible; NOTE: A woman who is planning to become pregnant or a man who plans to father a child while enrolled in this study or within 3 months after the last dose of study agent should likewise not be considered for this studyXx_NEWLINE_xXMale subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during those interruptions and for 6 months following IP discontinuation, even if he has undergone a successful vasectomyXx_NEWLINE_xXFemale subject must either be:Xx_NEWLINE_xXMale patients (with female sexual partners of childbearing potential) and female patients of childbearing potential who refuse to use effective methods of contraceptionXx_NEWLINE_xXMale or female patients who are sexually active and unwilling to take contraceptive measures for the duration of the treatments and for 3 months following discontinuation of AC480IVXx_NEWLINE_xXFemale subjects who are pregnant, or breastfeeding, or planning to become pregnant. Male subjects who plan to father a child while enrolled in this protocol.Xx_NEWLINE_xXFemale patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of the study drug.Xx_NEWLINE_xXFemale patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of study drug.Xx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xXPatients of childbearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation and chemotherapy on an unborn childXx_NEWLINE_xXFemale participants will be excluded from the trial if they become pregnant; female participants can use whichever method of contraception that they preferXx_NEWLINE_xXFemale subject of childbearing potential is neither pregnant nor lactating and must have a negative pregnancy test at the screen visit and a negative pregnancy test before dosing. All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective contraception (eg, implants, injectables, combined oral contraceptives, intrauterine device (IUD), sexual abstinence, vasectomy or vasectomized partner) for the duration of the studyXx_NEWLINE_xXFemale subjects of childbearing potential must not be pregnant or lactating at screeningXx_NEWLINE_xXPregnant or nursing female subjects, or female subjects of child bearing potential who refuse to take a pregnancy test prior to their enrollment in this studyXx_NEWLINE_xXIf female of reproductive age, or male partner of female of reproductive age, unwilling to use two medically reliable forms of birth control while on vismodegibXx_NEWLINE_xXBe female.Xx_NEWLINE_xXFemaleXx_NEWLINE_xXNon-pregnant female volunteerXx_NEWLINE_xXFor female patients of childbearing potential, all of the following criteria must be met:Xx_NEWLINE_xXPregnant femaleXx_NEWLINE_xXFOR THE 31 SUBJECTS ENROLLED IN YEAR 1: Pregnant femaleXx_NEWLINE_xXFemale, and a) currently pregnant or lactating, or b) of childbearing potential and unwilling to avoid pregnancy during the vaccine phase of study (beginning at day 1 and continuing until at least 4 weeks after all 3 vaccine doses have been administered)Xx_NEWLINE_xXPregnant femaleXx_NEWLINE_xXMale and female and all ethnic groups are eligibleXx_NEWLINE_xXFemale subjects of childbearing potential and male subjects with female sexual partners of childbearing potential must agree to use an effective method of contraceptionXx_NEWLINE_xXFemale is not pregnant, and not breastfeeding; but if of childbearing potential agrees to follow contraceptive guidance during the treatment period and for at least 12 weeks after the last dose of study treatmentXx_NEWLINE_xXIf female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception must be: practicing two effective methods of birth controlXx_NEWLINE_xXIf female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the studyXx_NEWLINE_xXFemale patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination therapyXx_NEWLINE_xXIs male OR is female who is not of reproductive potential OR is female who is of reproductive potential and agrees to avoid becoming pregnant in the 28 days prior to receiving study drug, while receiving study drug and for at least 30 days after last dose of study drugXx_NEWLINE_xXMale or FemaleXx_NEWLINE_xXNormal volunteers, either male or femaleXx_NEWLINE_xXFemale subjects of non-childbearing potential may be enrolled in the study.Xx_NEWLINE_xXFemale subjects of childbearing potential may be enrolled inthe study, if the subject:Xx_NEWLINE_xXMen with a history of at least one male sexual partner            \r\n* Men is defined as those documented male at birth (including male-to-female transgendered persons)Xx_NEWLINE_xXFemale subjects of non-childbearing potential may be enrolled in the study.Xx_NEWLINE_xXFemale subjects of childbearing potential may be enrolled in the study, if the subject:Xx_NEWLINE_xXParticipant can be a male or a non-pregnant femaleXx_NEWLINE_xXNursing female subjectsXx_NEWLINE_xXPatients who are pregnant or lactating or who suspect they might be pregnant; serum pregnancy tests will be obtained prior to each set of multi-tracer PET scans in female patients that are not postmenopausal or surgically sterileXx_NEWLINE_xXSubjects who have contraindications for receiving Y-90 therapy and any routine procedures and imaging associated with Y-90 therapy, including subjects who are pregnant or are planning to become pregnant, will not be eligible to participate in this study. Female subjects who are of childbearing potential should inform her treating physician should she become pregnant at any time during the course of the studyXx_NEWLINE_xXPatients who are pregnant or lactating or who suspect they might be pregnant are not eligible; a serum pregnancy tests will be obtained 24-48 hours prior to the initial PET scan in female patients who are not postmenopausal or surgically sterileXx_NEWLINE_xXFemale participants of childbearing age must not be lactatingXx_NEWLINE_xXPatients who are pregnant or lactating or who suspect they might be pregnant; serum pregnancy tests will be obtained prior to each set of multi-tracer PET scans in female patients that are not postmenopausal or surgically sterileXx_NEWLINE_xXPregnancy or lactating femaleXx_NEWLINE_xXPatients who are pregnant or lactating or who suspect they might be pregnant; serum pregnancy tests will be obtained prior to the baseline and subsequent multi-tracer PET scans in female patients that are not postmenopausal or surgically sterileXx_NEWLINE_xXMale or female patientsXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding or female patients of reproductive potential who are not employing an effective method of birth control from starting vaccine, including dosing interruptions through 90 days after receipt of the last vaccine; refrain from egg cell donation while receiving vaccination and for at least 90 days after the last vaccineXx_NEWLINE_xXFemale subject must either:Xx_NEWLINE_xXPregnancy (if a female is of childbearing potentialdefined as a premenopausal female capable of becoming pregnant-a pregnancy test should be done)Xx_NEWLINE_xXPatients who are pregnant or lactating or who suspect they might be pregnant; serum pregnancy tests will be obtained prior to the baseline and subsequent multi-tracer PET scans in female patients that are not postmenopausal or surgically sterileXx_NEWLINE_xXNORMAL VOLUNTEERS: If female, pregnant or breastfeeding at time of consentXx_NEWLINE_xXPregnancy (for female patients)Xx_NEWLINE_xXPatient: FemaleXx_NEWLINE_xXFemaleXx_NEWLINE_xXMale sterilization (at least 6 months prior to enrolling). For female patients on the study the vasectomized male partner should be the sole partner for that patient.Xx_NEWLINE_xXFemale who is lactating/breastfeeding.Xx_NEWLINE_xXFemale participants who:Xx_NEWLINE_xX